Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 17/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 6/20 | 0.35 |
| ▸ | CTSK | P43235 | 4/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870349 | 0.83 | SMN1; SMN2 (0.35) | CTSSCTSLCTSK | |
| SCHEMBL6062499 | 0.78 | CTSS (0.47) | CTSSMMP1MMP2MMP3MMP8 | |
| SCHEMBL6632644 | 0.78 | CTSS (0.47) | CTSSMMP1MMP2MMP3MMP8 | |
| SCHEMBL4449644 | 0.75 | CTSS (0.44) | CTSSCTSLCTSKRENCTSB | |
| SCHEMBL4454183 | 0.75 | CTSS (0.44) | CTSSCTSLCTSKRENCTSB | |
| SCHEMBL4459425 | 0.74 | CTSS (0.47) | CTSSMMP1MMP2MMP3MMP8 | |
| SCHEMBL5870402 | 0.72 | CTSS (0.42) | CTSSCTSLCTSKRENCTSB | |
| SCHEMBL12196236 | 0.71 | CTSS (0.49) | CTSSMMP1MMP2MMP3MMP8 | |
| SCHEMBL12196292 | 0.71 | CTSS (0.49) | CTSSMMP1MMP2MMP3MMP8 | |
| SCHEMBL13677267 | 0.71 | CTSS (0.54) | CTSSCTSLCTSKREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132449-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| EP-1358174-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002057248-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | CTSS 24/4885BCHE 1080/4885ACHE 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.